Active Recombinant Human ANGPT2 Protein, His-tagged, Biotinylated
|Product Overview :||Recombinant Human ANGPT2(Tyr19-Phe496) fused with His tag at C-terminal was expressed in NS0, Biotinylated.|
- Gene Information
- Related Products
|Description :||Angiopoietin-2 (Ang-2; also ANGPT2) is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Mature human Ang-2 is 478 amino acids (aa) in length. It contains one coiled-coil domain (aa 166-248) that mediates multimerization, and a C-terminal fibrinogen-like domain (aa 275-495) that mediates receptor binding. Under reducing conditions, secreted monomeric Ang-2 is 65-66 kDa in size. Under non-reducing conditions, both natural and recombinant Ang-2 form 140 kDa dimers, 200 kDa trimers, and 250-300 kDa tetramers and pentamers. Alternative splicing generates a short isoform that lacks 52 amino acids (aa) preceding the coiled-coil domain. Mature human Ang-2 shares 86% aa sequence identity with mouse and rat Ang-2. Ang-2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel-Palade bodies. Both Ang-2 and the related Angiopoietin-1 (Ang-1) are ligands for the receptor tyrosine kinase Tie-2. While Ang-1 is a potent Tie-2 agonist, Ang-2 may act as either a Tie-2 antagonist or agonist, depending upon its state of multimerization. The higher the order of oligomer, the more effective Ang-2 becomes as a Tie-2 agonist. The short isoform appears to block the binding of either Ang-1 or full-length Ang-2 to Tie-2. Ang-2 functions as a pro-angiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang-2 is required for postnatal vascular remodeling, and it cooperates with Ang-1 during lymphatic vessel development. It mediates the up-regulation of ICAM-1 and VCAM-1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang-2 is up-regulated in both the endothelium and tumor cells of several cancers as well as in ischemic tissue. Its direct interaction with Integrins promotes tumor cell invasion. Ang-2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.|
|Source :||Mammalian cells|
|Predicted N Terminal :||Tyr19|
|Form :||Lyophilized from a 0.2 μm filtered solution in MOPS, NaCl, CHAPS and PEG with BSA as a carrier protein.|
|Bio-activity :||Measured by its ability to activate Tie-2 in C6 rat glial cells transfected with human Tie-2. 0.2 μg/mL of Biotinylated Recombinant Human Angiopoietin-2 significantly induces phosphorylation of human Tie-2.|
|Molecular Mass :||56 kDa (unlabeled)|
|Protein length :||Tyr19-Phe496|
|Endotoxin :||<0.10 EU per 1 μg of the protein by the LAL method.|
|Purity :||>95%, by SDS-PAGE with silver staining|
|Notes :||Structure / Form: Oligomer, biotinylated via sugar residues|
|Storage :||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile
|Reconstitution :||Reconstitute at 100 μg/mL in PBS.|
|Gene Name :||ANGPT2 angiopoietin 2 [ Homo sapiens ]|
|Official Symbol :||ANGPT2|
|Synonyms :||ANGPT2; angiopoietin 2; angiopoietin-2; Ang2; ANG-2; Tie2-ligand; angiopoietin-2B; angiopoietin-2a; ANG2; AGPT2;|
|Gene ID :||285|
|mRNA Refseq :||NM_001118887|
|Protein Refseq :||NP_001112359|
|UniProt ID :||O15123|
|◆ Recombinant Protein|
|ANGPT2-2467H||Recombinant Human ANGPT2 Protein, His (Fc)-Avi-tagged||+Inquiry|
|ANGPT2-325R||Recombinant Rat ANGPT2 Protein, His (Fc)-Avi-tagged||+Inquiry|
|ANGPT2-1067H||Recombinant Human ANGPT2 Protein (Met1-Gln248 and Lys275-Phe496), MlgG2a Fc-tagged||+Inquiry|
|ANGPT2-696H||Recombinant Human ANGPT2 Protein, His-tagged||+Inquiry|
|Angpt2-2163M||Active Recombinant Mouse Angpt2 Protein, C-6×His tagged||+Inquiry|
|ANGPT2-2228HCL||Recombinant Human ANGPT2 cell lysate||+Inquiry|
|ANGPT2-001MCL||Recombinant Mouse ANGPT2 cell lysate||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (15)Ask a question
Like any other therapeutic agent, ANGPT2 inhibitors may have side effects and risks. Common side effects reported in clinical trials include fatigue, headache, gastrointestinal disturbances, and hypertension. However, the specific side effects and risks may vary depending on the individual drug and its mechanism of action. It is important to consult with healthcare professionals and closely monitor patients during treatment to manage any potential adverse effects.
Yes, ANGPT2 inhibitors can be used in combination with other therapies. Combining ANGPT2 inhibitors with other anti-angiogenic agents, chemotherapy, or immunotherapy may have synergistic effects and enhance treatment outcomes. Additionally, they may be combined with conventional treatments in diseases where ANGPT2 is implicated in disease progression or resistance to therapy. Clinical trials are ongoing to evaluate the safety and efficacy of these combination therapies.
Several compounds have been identified as inhibitors of ANGPT2. These include antibodies that specifically target ANGPT2, as well as small molecule inhibitors that interfere with its activity. In contrast, there are no known activators of ANGPT2 identified to date.
Some studies suggest that certain natural compounds or dietary factors can modulate ANGPT2 levels. For example, green tea catechins, resveratrol, and curcumin have demonstrated potential in reducing ANGPT2 expression or activity in preclinical studies. However, more research is needed to determine their efficacy and safety in clinical settings.
Yes, ANGPT2 expression is regulated by various genetic and epigenetic factors. Single nucleotide polymorphisms (SNPs) in the ANGPT2 gene have been associated with altered ANGPT2 expression levels and susceptibility to certain diseases. Additionally, epigenetic modifications, such as DNA methylation and histone modifications, can also regulate ANGPT2 expression by influencing the accessibility of the gene for transcription.
One of the challenges in the development and use of ANGPT2 inhibitors is identifying the patient populations that would benefit most from this therapy. Understanding the precise mechanisms of ANGPT2 in different diseases and identifying reliable biomarkers for patient selection are important areas of future research.
ANGPT2 inhibitors have shown promise in various therapeutic applications. In cancer, blocking ANGPT2 can help normalize tumor blood vessels, improve drug delivery to the tumor, and enhance the effectiveness of anti-cancer therapies. Additionally, ANGPT2 inhibitors may also have potential in the treatment of other diseases involving abnormal angiogenesis, such as age-related macular degeneration, diabetic retinopathy, and inflammatory disorders.
In cancer, ANGPT2 is often upregulated and contributes to tumor angiogenesis and progression. It promotes vessel destabilization, allowing for the formation of leaky and irregular blood vessels within tumors. This abnormal vasculature can support tumor growth, metastasis, and resistance to therapies.
Yes, there are ongoing clinical trials investigating the therapeutic potential of targeting ANGPT2 in cancer and other diseases. These trials evaluate the efficacy and safety of ANGPT2 inhibitors either alone or in combination with other treatments. These studies aim to elucidate whether blocking ANGPT2 can have clinical benefits, such as inhibiting tumor growth, improving patient outcomes, or overcoming therapy resistance.
ANGPT2 has been explored as a potential biomarker in various diseases, including cancer, cardiovascular diseases, and sepsis. Elevated levels of ANGPT2 have been associated with disease progression and poor prognosis in some cases. However, further research is still needed to establish its clinical utility as a diagnostic or prognostic biomarker.
ANGPT2 plays a role in inflammation and immune responses by promoting vascular leakiness and enhancing the recruitment of immune cells to the site of inflammation. It is produced by immune cells, such as macrophages and neutrophils, in response to inflammatory stimuli. ANGPT2 can disrupt endothelial integrity, facilitating the extravasation of immune cells and contributing to the inflammatory process.
Yes, some therapeutic strategies aim to restore the balance between ANGPT1 and ANGPT2. These strategies include the administration of exogenous ANGPT1 or ANGPT2 inhibitors to regulate angiogenesis and vascular stability. The goal is to promote a more balanced and controlled angiogenic response, which may have therapeutic benefits in various diseases characterized by aberrant angiogenesis.
Yes, there are several ongoing clinical trials investigating the use of ANGPT2 inhibitors in various diseases. These trials assess the safety, efficacy, and optimal dosing of ANGPT2 inhibitors either as monotherapy or in combination with other treatments. Some of the diseases being studied include solid tumors, diabetic macular edema, acute myeloid leukemia, and idiopathic pulmonary fibrosis, among others. These trials aim to determine the potential of ANGPT2 inhibitors as a therapeutic option in these diseases.
ANGPT2 inhibitors function as anti-angiogenic agents by blocking the activation of ANGPT2 and its interaction with the Tie2 receptor. Compared to other anti-angiogenic therapies, such as VEGF inhibitors, ANGPT2 inhibitors target a different pathway involved in angiogenesis regulation.
ANGPT2 is produced by various cell types, including endothelial cells, immune cells, and certain cancer cells. Its production can be induced by different stimuli, such as hypoxia, inflammation, and growth factors.
Customer Reviews (5)Write a review
The ANGPT2 protein offers exceptional quality that meets the rigorous demands of experimental research. -
Whether studying angiopoietin signaling pathways, vascular remodeling, or endothelial cell biology, the ANGPT2 protein is an invaluable tool for researchers. -
What sets the ANGPT2 protein apart is not only its outstanding quality but also the excellent technical support provided by the manufacturer. -
the ANGPT2 protein's versatility extends beyond its proven usefulness in in vitro experiments. -
Its purity, consistency, and reliable performance make it a top choice for a wide range of applications. -
Ask a Question for All ANGPT2 Products
Required fields are marked with *
My Review for All ANGPT2 Products
Required fields are marked with *